Download PDF
Horm Metab Res 2002; 34(6): 293-302
DOI: 10.1055/s-2002-33257
Original Basic
© Georg Thieme Verlag Stuttgart · New York

Anabolic Effects of Recombinant Human Parathyroid Hormone (1 - 84) and Synthetic Human Parathyroid Hormone (1 - 34) on the Mandibles of Osteopenic Ovariectomized Rats with Maxillary Molar Extraction

T.  Kawane 1 , S.  Takahashi 1 , H.  Saitoh 2 , H.  Okamoto 1 , N.  Kubodera 2 , N.  Horiuchi 1
  • 1Departments of Biochemistry and Periodontics, Ohu University School of Dentistry, Koriyama, Japan
  • 2Fuji Gotemba Research Laboratory, Chugai Parmaceutical, Gotemba, Japan
Further Information

Publication History

Received 18 June 2001

Accepted after Revision 25 February 2002

Publication Date:
12 August 2002 (online)

Also available at
    Permissions and Reprints

Abstract

In rodent osteoporosis models such as ovariectomized (OVX) rats, intermittently administered human parathyroid hormone (hPTH) has an anabolic effect in vertebrae and long bones. In the present experiments, subcutaneously injected hPTH(1 - 34) or hPTH(1 - 84) dose- and time-dependently increased bone mineral density (BMD) as measured by dual energy X-ray absorptiometry in mandibles, L2 to L4 vertebrae and femurs of such rats. The highest dose (15.9 nmol/kg, s. c.) of either peptide given four times weekly for 10 weeks completely reversed the effects of overiectomy on BMD. Significant elevation in lumbar BMD after 10 weeks was observed with hPTH(1 - 34) or hPTH(1 - 84) at 1.1 nmol/kg, whereas hPTH(1 - 34) at 1.1 and 4.2 nmol/kg significantly increased BMD of the whole bone and the metaphysis of the femur and the diaphysis of the bone, respectively. In contrast, significant effects of hPTH(1 - 84) administration on BMD increase in the femur were observed at 4.2 and 15.9 nmol/kg in the whole bone and the metaphysis, and in the diaphysis, respectively. Maxillary molar extraction left mandibular BMD in rats with intact ovaries unchanged, but significantly decreased mandibular BMD in OVX rats. Administration of hPTH(1 - 84) for 10 weeks in OVX rats without or with extraction significantly increased BMD in the mandibular molar region at doses of 15.9 and 4.2 nmol/kg, respectively, indicating that efficacy was increased by extraction. A significant BMD increase in the molar region in OVX rats with extraction occurred at only 1.1 nmol/kg of hPTH(1 - 34) and 4.2 nmol/kg of hPTH(1 - 84). Also, BMD of the ramus region was increased by administration of both peptides to a lesser extent than that of the molar region in these rats. Thus, intermittent administration of hPTH, especially hPTH(1 - 34), has an anabolic effect on bone, particularly alveolar bone. Such treatment may increase alveolar bone mass in postmenopausal women with osteoporosis.

Key words

Intermittent Administration - Bone Mineral Density - Bone Formation - Osteoporosis

References

  • 1 Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures.  Bone. 1994;  15 377-386
    CrossrefPubMedGoogle Scholar
  • 2 Christiansen C. Prevention and treatment of osteoporosis: a review of current modalities.  Bone. 1992;  13 Suppl. 1 S35-S39
    PubMedGoogle Scholar
  • 3 Lane N E, Thompson J M, Strewler G J, Kinney J H. Intermittent treatment with human parathyroid hormone (hPTH 1 - 34) increased trabecular bone volume but not connectivity in osteopenic rats.  J Bone Miner Res. 1995;  10 1470-1477
    PubMedGoogle Scholar
  • 4 Kimmel D B, Recker R R, Gallagher J C, Vaswani A S, Aloia J F. A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects.  Bone Miner. 1990;  11 217-235
    CrossrefPubMedGoogle Scholar
  • 5 Weinstein R S, Hutson M S. Decreased trabecular width and increased trabecular spacing contribute to bone loss with aging.  Bone. 1987;  8 137-142
    CrossrefPubMedGoogle Scholar
  • 6 Christiansen C, Lindsay R. Estrogens, bone loss and preservation.  Osteoporosis International. 1990;  1 7-13
    CrossrefPubMedGoogle Scholar
  • 7 Margolis R N, Canalis E, Partridge N C. Invited review of a workshop: anabolic hormones in bone: basic research and therapeutic potential.  J Clin Endocrinol Metab. 1996;  81 872-877
    CrossrefPubMedGoogle Scholar
  • 8 Reeve J, Davies U M, Hesp R, McNally E, Katz D. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.  British Medical Journal. 1990;  301 314-318
    PubMedGoogle Scholar
  • 9 Reeve J, Meunier P J, Parsons J A, Bernat M, Bijvoet O L, Courpron P, Edouard C, Klenerman L, Neer R M, Renier J C, Slovik D, Vismans F J, Potts Jr. J T. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.  Br Med J. 1980;  280 1340-1344
    CrossrefPubMedGoogle Scholar
  • 10 Slovik D M, Rosenthal D I, Doppelt S H, Potts Jr. J T, Daly M A, Campbell J A, Neer R M. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1 - 34) and 1,25-dihydroxyvitamin D.  J Bone Miner Res. 1986;  1 377-381
    PubMedGoogle Scholar
  • 11 Frost H M, Jee W SS. On the rat model of human osteopenias and osteoporoses.  Bone Miner. 1992;  18 227-236
    CrossrefPubMedGoogle Scholar
  • 12 Kalu D N. The ovariectomized rat model of postmenopausal bone loss.  Bone Miner. 1991;  15 175-191
    CrossrefPubMedGoogle Scholar
  • 13 Dempster D W, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone.  Endocrine Rev. 1993;  14 690-709
    CrossrefPubMedGoogle Scholar
  • 14 Baumann B D, Wronski T J. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.  Bone. 1995;  16 247-253
    CrossrefPubMedGoogle Scholar
  • 15 Meng X W, Liang X G, Birchman R, Wu D D, Dempster D W, Lindsay R, Shen V. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.  J Bone Miner Res. 1996;  11 421-429
    PubMedGoogle Scholar
  • 16 Mitlak B H, Burdette-Miller P, Schoenfeld D, Neer R M. Sequential effects of chronic human PTH (1 - 84) treatment of estrogen-deficiency osteopenia in the rat.  J Bone Miner Res. 1996;  11 430-439
    PubMedGoogle Scholar
  • 17 Dobnig H, Turner R T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells.  Endocrinology. 1995;  136 3632-3638
    CrossrefPubMedGoogle Scholar
  • 18 Tam C S, Heersche J NM, Murray T M, Parsons J A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration.  Endocrinology. 1982;  110 506-512
    CrossrefPubMedGoogle Scholar
  • 19 Miller S C, Bowman B M, Miller M A, Bagi C M. Calcium absorption and osseous organ-, tissue-, and envelope-specific changes following ovariectomy in rats.  Bone. 1991;  12 439-446
    CrossrefPubMedGoogle Scholar
  • 20 Elovic R P, Hipp J A, Hayes W C. Ovariectomy decreases the bone area fraction of the rat mandible.  Calcified Tissue Int. 1995;  56 305-310
    PubMedGoogle Scholar
  • 21 Miller S C, Hunziker J, Mecham M, Wronski T J. Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats.  J Dent Res. 1997;  76 1471-1476
    PubMedGoogle Scholar
  • 22 Bonofiglio D, Maggiolini M, Catalano S, Marsico S, Aquila S, Ando S. Bone mineral density is inversely related to parathyroid hormone in adolescent girls.  Horm Metab Res. 2001;  33 170-174
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Kanzawa M, Sugimoto T, Kobayashi T, Kobayashi A, Chihara K. Association between parathyroid hormone (PTH)/PTH-related peptide receptor gene polymorphism and the extent of bone mass reduction in primary hyperparathyroidism.  Horm Metab Res. 2000;  32 355-358
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Gomez J M, Gomez N, Fiter J, Soler J. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.  Horm Metab Res. 2000;  32 66-70
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 D’Erasmo E, Pisani D, Ragno A, Raejntroph N, Letizia C, Acca M. Relationship between serum albumin and bone mineral density in postmenopausal women and in patients with hypoalbuminemia.  Horm Metab Res. 1999;  31 385-388
    PubMedGoogle Scholar
  • 26 Elovic R P, Hipp J A, Hayes W C. Maxillary molar extraction causes increased bone loss in the mandible of ovariectomized rats.  J Bone Miner Res. 1995;  10 1087-1093
    PubMedGoogle Scholar
  • 27 Gardella T J, Rubin D, Abou-Samra A-B, Keutmann H T, Potts J T , Kronenberg H M, Nussbaum S R. Expression of human parathyroid hormone-(1 - 84) in Escherichia coli as a factor X-cleavable fusion protein.  J Biol Chem. 1990;  265 15 854-15 859
    PubMedGoogle Scholar
  • 28 Torres R, de la Piedra C, Rapado A. Clinical usefulness of serum tartrate-resistant acid phosphatase in Paget’s disease of bone: correlation with other biochemical markers of bone remodelling.  Calcified Tissue Int. 1991;  49 14-16
    PubMedGoogle Scholar
  • 29 Frolik C A, Cain R L, Sato M, Harvey A K, Chandrasekhar S, Black E C, Tashjian A H, Hock J M. Comparison of recombinant human PTH(1 - 34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1 - 34) (RS-66 271): In vitro activity and in vivo pharmacological effects in rats.  J Bone Miner Res. 1999;  14 163-172
    PubMedGoogle Scholar
  • 30 Kimmel D B, Bozzato R P, Kronis K A, Coble T, Sindrey D, Kwong P, Recker R R. The effect of recombinant human (1 - 84) or synthetic human (1 - 34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats.  Endocrinology. 1993;  132 1577-1584
    CrossrefPubMedGoogle Scholar
  • 31 Lane N E, Sanchez S, Modin G W, Genant H K, Pierini E, Arnaud C D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.  J Clin Invest. 1998;  102 1627-1633
    PubMedGoogle Scholar
  • 32 Mosekilde L, Søgaard C H, Danielsen C C, Tørring O, Nilsson M HL. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1 - 34) and hPTH-(1 - 84).  Endocrinology. 1991;  129 421-428
    PubMedGoogle Scholar
  • 33 Rittmaster R S, Bolognese M, Ettinger M P, Hanley D A, Hodsman A B, Kendler D L, Rosen C J. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.  J Clin Endocrinol Metab. 2000;  85 2129-2134
    CrossrefPubMedGoogle Scholar
  • 34 Stanislaus D, Devanarayan V, Hock J M. In vivo comparison of activated protein-1 gene activation in response to human parathyroid hormone (hPTH)(1 - 34) and hPTH(1 - 84) in the distal femur metaphyses of young mice.  Bone. 2000;  27 819-826
    CrossrefPubMedGoogle Scholar
  • 35 Wronski T J, Yen C-F, Qi H, Dann L M. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats.  Endocrinology. 1993;  132 823-831
    CrossrefPubMedGoogle Scholar
  • 36 Nguyen-Yamamoto L, Rousseau L, Brossard J-H, Lepage R, D’Amour P. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor.  Endocrinology. 2001;  142 1386-1392
    CrossrefPubMedGoogle Scholar
  • 37 Kalu D N, Liu C-C, Hardin R R, Hollis B W. The aged rat model of ovarian hormone deficiency bone loss.  Endocrinology. 1989;  124 7-16
    PubMedGoogle Scholar
  • 38 Toolan B C, Shea M, Myers E R, Borchers R E, Seedor J G, Quartuccio H, Rodan G, Hayes W C. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats.  J Bone Miner Res. 1992;  7 1399-1406
    PubMedGoogle Scholar
  • 39 Andersson N, Lindberg M K, Ohlsson C, Andersson K, Ryberg B. Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice.  J Endocrinol. 2001;  170 529-537
    CrossrefPubMedGoogle Scholar
  • 40 Harter L V, Hruska K A, Duncan R L. Human osteoblast-like cells respond to mechanical strain with increased bone matrix protein production independent of hormonal regulation.  Endocrinology. 1995;  136 528-535
    CrossrefPubMedGoogle Scholar
  • 41 Toma C D, Ashkar S, Gray M L, Schaffer J L, Gerstenfeld L C. Signal transduction of mechanical stimuli is dependent on microfilament integrity: identification of osteopontin as a mechanically induced gene in osteoblasts.  J Bone Miner Res. 1997;  12 1626-1636
    PubMedGoogle Scholar
  • 42 Salter D M, Robb J E, Wright M O. Electrophysiological responses of human bone cells to mechanical stimulation: evidence for specific integrin function in mechanotransduction.  J Bone Miner Res. 1997;  12 1133-1141
    PubMedGoogle Scholar
  • 43 Wozniak M, Fausto A, Carron C P, Meyer D M, Hruska K A. Mechanically strained cells of the osteoblast lineage organize their extracellular matrix through unique sites of alphavbeta3-integrin expression.  J Bone Miner Res. 2000;  15 1731-1745
    PubMedGoogle Scholar
  • 44 Dobnig H, Turner R T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells.  Endocrinology. 1995;  136 3632-3638
    CrossrefPubMedGoogle Scholar
  • 45 LaFlamme S E, Auer K L. Integrin signaling.  Semin Cancer Biol. 1996;  7 111-118
    CrossrefPubMedGoogle Scholar
  • 46 Hunziker J, Wronski T J, Miller S C. Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone.  J Dent Res. 2000;  79 1431-1438
    PubMedGoogle Scholar
  • 47 Nakajima M, Ejiri S, Tanaka M, Toyooka E, Kohno S, Ozawa H. Effect of intermittent administration of human parathyroid hormone (1 - 34) on the mandibular condyle of ovariectomized rats.  J Bone Miner Metab. 2000;  18 9-17
    CrossrefPubMedGoogle Scholar
  • 48 Hodsman A B, Steer B M, Fraher L J, Drost D J. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1 - 38) and salmon calcitonin in osteoporotic patients.  Bone Miner. 1991;  14 67-83
    CrossrefPubMedGoogle Scholar
  • 49 Inomata N, Akiyama M, Kubota N, Jüppner H. Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1 - 84).  Endocrinology. 1995;  136 4732-4740
    CrossrefPubMedGoogle Scholar
  • 50 Kaji H, Sugimoto T, Kanatani M, Miyauchi A, Kimura T, Sakakibara S, Fukase M, Chihara K. Carboxyl-terminal parathyroid hormone fragments stimulate osteoclast-like cell formation and osteoclastic activity.  Endocrinology. 1994;  134 1897-1904
    CrossrefPubMedGoogle Scholar
  • 51 Divieti P, Inomata N, Chapin K, Singh R, Jüppner H, Bringhurst F R. Receptors for the carboxyl-terminal region of pth(1 - 84) are highly expressed in osteocytic cells.  Endocrinology. 2001;  142 916-925
    CrossrefPubMedGoogle Scholar
  • 52 Jüppner H, Abou-Samra A B, Freeman M, Kong X F, Schipani E, Richards J, Kolakowski L F, Hock J, Potts J T, Kronenberg H M, Segre G V. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide.  Science. 1991;  254 1024-1026
    CrossrefPubMedGoogle Scholar

N. Horiuchi, D.D.S., Ph.D.

Department of Biochemistry,

Ohu University School of Dentistry

Koriyama 963-8611 · Japan

Fax: + 81 (249) 38-91 92

Email: fwga 4746@mb.infoweb.ne.jp